A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations

The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an important part of the drug development process as well as for routine analysis and quality control of commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are well documented by a variety of methods, there are few publications about the determination of udenafil, lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug concentration in biological matrices and pharmaceutical formulations of these four drugs.

A introdução da terapia oral com inibidores da fosfodiesterase tipo 5, em 1998, revolucionou o tratamento da disfunção erétil. A disfunção erétil é o problema sexual mais comum em homens. Muitas vezes tem um efeito profundo nas relações íntimas e na qualidade de vida. A análise de produtos farmacêuticos é uma parte importante do processo de desenvolvimento de fármacos, bem como para a análise de rotina e controle de qualidade das formulações comerciais. Enquanto a determinação do citrato de sildenafila, vardenafila e tadalafila está bem documentada por uma variedade de métodos, existem poucas publicações sobre a determinação de udenafila, carbonato de lodenafila, mirodenafila e avanafila. O artigo apresenta uma breve revisão do mecanismo de ação, efeitos adversos, farmacocinética e os mais recentes métodos analíticos, que podem determinar a concentração do fármaco em matrizes biológicas e formulações farmacêuticas destes quatro fármacos.

Intracavernosal pharmacotherapy; Comparative study of the 3Ps solution with prostaglandin E1 [PGE1]

Intracavernosal pharmacotherapy has revolutionized treatment of erectile dysfunction. In this study, 84 patients with impotence were classified into two groups [42 for each] and they were injected with PGE1 alone [20 ug/ml] and "3Ps" solution containing papaverine [12 mg/ml], PGE1 [9 ug/ml] and phentolamine [1 mg/ml] in a double blind-crossover maneuver of treatment. Prostaglandin El alone induced full rigid-satisfactory erection in 71.4% of treated patients, with mean time of latency between injection of the drug and start of tumescence of 14 minutes and average duration of erection of 131.8 minutes. In the "3Ps" solution, full rigid-satisfactory erection was obtained in 90.5% of the treated cases, with a latency period of 8.4 minutes and duration of erection of 182.8 minutes. Penile self stimulation was required in the PGE1-alone treated group in 76.2% of cases, while it was only required in 52.4% of cases in the "3Ps" treated group of patients. Side effects of both drug regimens were minimal and not severe, and they were less frequently occurring in the "3Ps" solution treated group of patients. It was concluded that the use of PGE1 in combination with other vasoactive drugs makes the combination more durable in action and with less side effects than if the drug was used alone. Also, the dosage required for each vasoactive agent is less than that if each drug is used alone

La primera consulta del paciente con disfunción sexual erectil / The first consultation of the patient with erectile sexual dysfunction

En este artículo exponemos los métodos actuales para el diagnóstico de la disfunción sexual eréctil en el hombre. Utilizamos en la primera consulta el método clínico para delimitar los factores orgánicos y psicológicos en un paciente dado. Se relacionan las investigaciones paraclínicas que pudieran indicarse en esta primera consulta

Valoracion del tratamiento homeopatico en el stress, la impotencia y la eyaculacion precoz / Evaluation of homeopathic treatment in stress, impotence and premature ejaculation

Se estudiaron en una investigacion abierta 60 pacientes del sexo masculino padeciendo stress, impotencia y eyaculacion precoz, cuyas edades fluctuaban entre los 18 y 62 anos (edad promedio 40 anos), de los cuales 34 prestaban servicios en diferentes bancos: 10 se desempenaban como profesionistas 6 eran estudiantes de diversas disciplinas; 5 trabajaban en ocupaciones varias y los 5 restantes, habian pertenecido a instituciones bancarias pero a la sazon estaban jubilados. 50 de dichos casos correspondieron a varones circuncidados, mientras que en 44 individuos existia tabaquismo intenso, moderado y ocasional. 47 sujetos de estudio, bebian mas de una taza de cafe al dia, 47 pacientes consumian diariamente una o mas bebidas gaseosas a base de cola y 37 tomaban una o mas bebidas alcoholicas habitualmente. En 6 casos que cursaban simultaneamente con hipertension, se observo impotencia consecutiva al tratamiento previo clortalidona y metildopa, mientras que la totalidad de los casos tratados (100%), padecian stress en diferentes grados; en 37 se encontro impotencia psiquica (61%), y los otros 23 presentaban eyaculacion precoz (39%). Los 60 pacientes recibieron una dosis diaria de una tableta No.4 de trituracion de Phosphoricum acidum 3D, Glutamicum acidum 3D y Strychninum 3D antes de los alimentos y alternando los medicamentos, durante un lapso que fluctuo entre 15 y 60 dias con excelentes resultados en 49 casos (82%), siendo nulos o poco notables en 11 pacientes (18%). Asimismo todos los casos (100%), fueron tratados exclusivamente por homeopatia y seleccionados, individualizados y repertorizados siguiendo la tecnica homeopatica